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Hypophysitis is a rare condition describing inflammation of the pituitary gland. The disorder 
may be primary, involving the pituitary gland itself, or secondary, due to other diseases or 
drugs. The incidence of primary hypophysitis is one case per 9 million [1]; however, new 
forms of the condition are increasingly diagnosed and the actual occurrence appears to be 
higher. Symptoms are connected with the presence of a pathological mass in the pituitary area 
and hormonal abnormalities. The diagnosis is based on clinical presentation, laboratory tests, 
and imaging. Deficiency of ACTH is found in 60% of cases, followed by deficits of LH/FSH 
in 52%, TSH in 52%, ADH in 39%, GH in 38%, and a high PRL level in 37% of cases [2]. 
Magnetic resonance remains the gold standard for imaging. The homogenous enhancement of 
the pituitary gland, thickening of a non-deviated stalk, and a missing posterior lobe signal in a 
T1 modality are the most characteristic radiological changes [3]. Hormonal substitution is the 
cornerstone of therapy. In cases with severe neurological symptoms, high-dose steroids or 
2 
 
other immunosuppressant drugs are used. Surgery and radiotherapy are options for patients 
with significant consequences of mass-effect and those resistant to pharmacological treatment. 
Hypophysitis often leads to atrophy of the pituitary gland. More than 70% of patients require 
long-term hormonal substitution [4]. 
A 22-year-old patient without a significant past medical history was admitted to a regional 
hospital with a four-month history of excessive thirst and frequent urination. The occurrence 
of polydipsia and polyuria was associated with respiratory tract infection. The patient’s 
hobbies included amateur kickboxing, but he denied any head trauma. Based on a water 
deprivation test, diabetes insipidus was diagnosed, with substantial improvement in symptom 
control after administration of desmopressin. MR of the pituitary area revealed a thickened 
non-deviated stalk of 4.5 mm and a missing posterior pituitary lobe signal. During several 
hospitalisations in the Endocrinology Department, gonadal and somatotropic axis 
insufficiencies as well as mild hyperprolactinaemia were discovered. Adequate control of 
diabetes insipidus was confirmed. Thyroid and adrenal gland function were unaffected. To 
exclude secondary causes of the observed symptoms, multiple imaging and biochemical 
studies were performed with unremarkable findings. The patient was diagnosed with 
lymphocytic hypophysitis. In a control MR the pituitary stalk was enlarged to 5 × 5 × 5 mm 
and the pituitary lobes did not show any deviations. Due to the lack of severe neurological 
symptoms, treatment was continued with desmopressin only. During a follow-up assessment, 
the stalk size normalised to 2.5 × 3 × 3 mm on MR (Fig. 1). Prolactin and testosterone values 
were within normal limits. Unfortunately, the diabetes insipidus was persistent, and only a 
transient improvement in IGF-1 levels was observed (Tab. I).  
This case report shows that diabetes insipidus may be the first manifestation of developing 
hypophysitis. The treatment should be individualised and tailored to each case. Patients 
presenting with mild symptoms can be approached with watchful waiting as a therapeutic 
option because hormonal and imaging improvements occur during the course of the disease 
[5]. Further research is needed to create algorithms for the management of hypophysitis. 
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Figure 1. Radiological improvement in a 22-year-old patient with lymphocytic hypophysitis. 
Magnetic resonance imaging of the pituitary area. Panel A: June 2018. Panel B: January 2019. 
Courtesy of Department of Radiology, University Hospital, Krakow 
 
 
Table I. Hormonal assessment 
Hormone [range] IV 2018 VI 2018 IX 2018 I 2019 VI 2019 
ACTH [6.0–56.0 pg/mL] 42.0 41.6 45.0 55.0 – 
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Cortisol — morning 11.6 22.1 18.8 19.3 15.1 
TSH [0.27–4.20 uIU/mL] 2.94 2.20 2.27 2.22 3.67 
fT4 [12.0–22.0 pmol/L] 13.4 12.5 13.5 16.6 16.65 
PRL — morning [50.0–460.0 
uIU/mL] 
384.0 792.4 263.0 302.1 311.7 
LH [1.70–8.60 mIU/mL] 4.07 4.33 4.75 5.18 5.34 
FSH [1.5–12.4 mIU/mL] 2.31 2.34 2.92 2.82 2.75 
Testosterone [8.64–29.00 nmol/] 5.66 5.77 5.96 9.09 9.34 
GH [0.2–10.0 uIU/mL] 1,3 1.2 0.7 0.6 – 
IGF-1 [235.0–408.0 ng/mL] 225.0 164.0 265.0 253.0 215.0 
Urine specific gravity [1.005–1.030 
g/mL] 
1.016 1.021 1.017 1.011 1.003 
ACTH — adrenocorticotropic hormone; FSH — follicle-stimulating hormone; fT4 — free 
thyroxine; GH — growth hormone; IGF-1 — insulin-like growth factor 1; LH — luteinising 
hormone; PRL — prolactin; TSH — thyroid-stimulating hormone 
 
